You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus
|
|---|---|
| Published in |
Journal of Crohn's and Colitis Supplements, January 2012
|
| DOI | 10.1016/j.crohns.2011.11.001 |
| Pubmed ID | |
| Authors |
Walter Reinisch, Gert Van Assche, Ragnar Befrits, William Connell, Geert D'Haens, Subrata Ghosh, Pierre Michetti, Thomas Ochsenkühn, Remo Panaccione, Stefan Schreiber, Mark S. Silverberg, Dario Sorrentino, C. Janneke van der Woude, Séverine Vermeire, Julian Panes |
| Abstract |
Infliximab is currently the only biologic approved for treatment of adults with moderate to severe, active ulcerative colitis (UC) unresponsive to conventional therapies. It rapidly controls symptoms, induces and sustains steroid-free remission, stimulates mucosal healing, and reduces serious complications. Although infliximab tends to be reserved for patients with severe disease, it may be even more beneficial for moderate disease earlier in the disease course. Therefore, it is important to identify which patients are candidates for infliximab therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Mexico | 1 | 1% |
| Denmark | 1 | 1% |
| Czechia | 1 | 1% |
| Unknown | 71 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 19% |
| Student > Master | 11 | 15% |
| Other | 8 | 11% |
| Student > Postgraduate | 7 | 9% |
| Professor > Associate Professor | 7 | 9% |
| Other | 17 | 23% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 56% |
| Agricultural and Biological Sciences | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Computer Science | 2 | 3% |
| Social Sciences | 2 | 3% |
| Other | 10 | 13% |
| Unknown | 11 | 15% |